Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
4.180
-0.090 (-2.11%)
At close: Nov 19, 2025, 4:00 PM EST
4.200
+0.020 (0.48%)
After-hours: Nov 19, 2025, 7:32 PM EST
Relmada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Relmada Therapeutics stock have a consensus rating of "Buy" and an average price target of $5.50, which forecasts a 31.58% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $10.
Price Target: $5.50 (+31.58%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Relmada Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold → Buy Upgrades $1 → $10 | Hold → Buy | Upgrades | $1 → $10 | +139.23% | Nov 19, 2025 |
| Mizuho | Mizuho | Buy → Hold Downgrades $23 → $1 | Buy → Hold | Downgrades | $23 → $1 | -76.08% | Dec 5, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $1 | Buy → Hold | Downgrades | $10 → $1 | -76.08% | Dec 4, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +211.00% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | -52.15% | Jun 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.97
from -2.65
EPS Next Year
-1.73
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.03 | -1.79 | |||
| Avg | -1.97 | -1.73 | |||
| Low | -1.89 | -1.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.